(Q36602259)

15 August 2017

1 reference

title

Liposomal vaccines--targeting the delivery of antigen (English)

1 reference

15 August 2017

Joseph G Altin

1

1 reference

PubMed ID

16997712

15 August 2017

Christopher R Parish

series ordinal

2

1 reference

PubMed ID

16997712

15 August 2017

language of work or name

1 reference

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

40

1 reference

15 August 2017

1

1 reference

15 August 2017

39-52

1 reference

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

HIV vaccine design: insights from live attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Adverse events reported following live, cold-adapted, intranasal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococci infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunological ignorance of silent antigens as an explanation of tumor evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunotherapy of cancer with dendritic-cell-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells as vectors for immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells in tumor immunology and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells as therapeutic vaccines against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immune tolerance after delivery of dying cells to dendritic cells in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposomal delivery of CTL epitopes to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposomal delivery of antigen to human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Effect of liposomal antigens on the priming and activation of the immune system by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Pharmaceutical design of the liposomal antimicrobial agents for infectious disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunity in response to particulate antigen-delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunological memory in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Antigen-specific memory B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The world of TH1/TH2 subsets: first proof.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Lead and follow: the dance of the dendritic cell and T cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Interaction of dendritic cells with mycobacteria: where the action starts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Mucosal dendritic cells in immunity and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells: immunobiology and cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cell biology and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Production of type I interferons: plasmacytoid dendritic cells and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Development of murine plasmacytoid dendritic cell subsets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Phagocytosis of antigens by Langerhans cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

DC-SIGN and LFA-1: a battle for ligand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Endogenous ligands of Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The immunobiology of the TLR9 subfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Danger signals: a time and space continuum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Pattern recognition receptors: doubling up for the innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Interferon-gamma is an autocrine mediator for dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Cancer immunotherapy and heat-shock proteins: promises and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dynamic imaging of T cell-dendritic cell interactions in lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Activation of plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Tumor antigens recognized by T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Tumor-associated antigens: from discovery to immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Eradication of established tumors by CD8+ T cell adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunologic mechanisms of antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

TNF/TNFR family members in costimulation of T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

T cell anergy and costimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

A reassessment of the role of B7-1 expression in tumor rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Breaking down the barriers to cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Tuning tumor-specific T-cell activation: a matter of costimulation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Designer dendritic cells for tolerance induction: guided not misguided missiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Yin-Yang regulation of autoimmunity by DCs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cells: a journey from laboratory to clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cell immunotherapy: mapping the way.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Biophysical aspects of using liposomes as delivery vehicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The role of surface charge and hydrophilic groups on liposome clearance in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Lipid composition is important for highly efficient target binding and retention of immunoliposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposomes as carriers of antigens and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The immunological adjuvant and vaccine carrier properties of liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Interferon-gamma inductive effect of liposomes as an immunoadjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Synthesis of an amphiphilic tetraantennary mannosyl conjugate and incorporation into liposome carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Development of anti-p185HER2 immunoliposomes for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The development of IL-2 conjugated liposomes for therapeutic purposes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

A simple and rapid method for the preparation of plasma membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Regulation of antitumour immunity by CD1d-restricted NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Tumor-induced immune dysfunction: the macrophage connection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Role of immature myeloid Gr-1+ cells in the development of antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

The processing of antigens delivered as DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.027

10.1016/J.YMETH.2006.05.027

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16997712